COMP <GO>
ARDX vs MRK // OPERATING MARGIN
Ardelyx Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ARDX 2
— MRK 9
▲ OPERATING MARGIN LEADER: MRK
LAST: $3.10 (0.00%) • MKT CAP: $772.5M
operating-margins
-10.10%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
operating-margins
34.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARDX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARDX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.30% | 74.80% | +15.50 | ARDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.70% | 20.70% | -53.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.69% | 3.42% | -9.11 | MRK | /fcf-yield <GO> |
| Operating Margin ACTIVE | -10.10% | 34.30% | -44.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | -15.20% | 28.10% | -43.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 22.10% | 1.30% | +20.80 | ARDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.19 | -4.99 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.1 | 51.7 | -9.60 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $772.5M | $361.02B | -$360.25B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARDX REV | MRK REV | ARDX GROSS % | MRK GROSS % | ARDX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $407.3M | $65.01B | 90.3% | 74.8% | -$44.0M | $12.36B |
| FY 2024 | $333.6M | $64.17B | 84.8% | 76.3% | -$45.8M | $18.10B |
| FY 2023 | $124.5M | $60.12B | — | — | -$89.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARDX // BETA —
MRK // BETA 0.92